Do they have enough dosh for all our expansion hopes?14 May 2026 18:19
Shares climb a wall of worry, and after the price rises we’ve seen we’d be silly not to at least contemplate where our risks lie. Plainly the balance sheet, as is, looks great, but anyone who’s ever invested in small pharma knows that strong balance sheets don’t always mean there’s enough money. Imagine that SpaceX produce some huge order out of the woodwork, that requires a further step change in capacity. What’s more we then find that suppliers are offering 30 day credit against SpaceX offering 6 months settlement. (Americans aren’t known for early payment). Export guarantees/forfaiting/ bank finance etc will all help, but all the prospects in the world won’t hide the fact that today’s strong balance sheet comes under a bit more strain.
I may well be talking gibberish, and am happy to be put straight by someone that works in the real world rather than pontificates from an armchair (as I’m doing now). But we shouldn’t ignore that we’re invested in a small company playing in a seriously big industry. My guess is they’d love to have the balance sheet a bit stronger for what lies ahead.
I promise those who only look for mischief making in any thoughts, I haven’t sold any, and intend to let this one run as long as I can. I actually would expect an institutional placing which would be eagerly snapped up and would broaden the shareholder base.
So in fact what am I even worried about? Probably the risk that they don’t raise money. Ironic eh?